Photochemical Treatment of Platelet Concentrates with a Novel Psoralen and UVA to Enhance the Safety of Platelet Transfusions&lt;sub&gt;a&lt;/sub&gt;

Lin, Lily; Alfonso, Ryan; Behrman, B.; Corten, L.; Damonte, Patrizia; Dikeman, Roberta; Dupuis, Kent; Hei, Derek J.; Lin, Chao; Londe, Helen; Metchette, Ken; Phan, Tri M.; Reames, Aaron; Rheinschmidt, Margaret; Savoor, A.; Tessman, John W.; Corash, Laurence

doi:10.1159/000053391

Cited by 31 publications

(75 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients received conventional red cell products; more than 98% of red cell units were leukocyte reduced and 99% were gamma irradiated in both treatment groups. Data are summarized from Lin, 14 Lin et al, 15,16,18 Van Voorhis et al, 19,20 Dupuis et al, 21 Savoor et al, 22 and Sawyer et al 23 *Preliminary data; inactivation was performed in 35% B19-infected plasma and 65% PAS III (platelet additive solution III) in the absence of platelets. Studies included a 15-or 30-minute rest between addition of amotosalen and UVA treatment.…”

Section: Transfusion Strategiesmentioning

confidence: 99%

“…24,25 In vitro platelet function of PCT platelets was preserved following up to 7 days of storage. 15,16 Recovery and survival of radiolabeled PCT platelets in healthy subjects were reduced compared with conventional untreated platelets but within acceptable therapeutic ranges. 26 PCT and conventional untreated platelets resulted in comparable correction of prolonged bleeding times in patients with thrombocytopenia.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, strategies have been developed to treat the blood components in a way that will inactivate viruses, bacteria, protozoa, and contaminating leukocytes but retain therapeutic efficacy of the components. [13][14][15][16][17] Amotosalen HCl, formerly designated S-59, is a synthetic psoralen compound that intercalates into helical regions of DNA or RNA and on illumination with ultraviolet A (UVA) light reacts with pyrimidine bases to form internucleic and intranucleic acid strand cross-links. The photochemical treatment (PCT) inhibits replication of any DNA or RNA.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

McCullough

Vesole²,

Benjamin³

et al. 2004

Blood

365

579

View full text Add to dashboard Cite

We report a transfusion trial of platelets photochemically treated for pathogen inactivation using the synthetic psoralen amotosalen HCl. Patients with thrombocytopenia were randomly assigned to receive either photochemically treated (PCT) or conventional (control) platelets for up to 28 days. The primary end point was the proportion of patients with World Health Organization (WHO) grade 2 bleeding during the period of platelet support. A total of 645 patients (318 PCT and 327 control) were evaluated. The primary end point, the incidence of grade 2 bleeding (58.5% PCT versus 57.5% control), and the secondary end point, the incidence of grade 3 or 4 bleeding (4.1% PCT versus 6.1% control), were equivalent between the 2 groups (P ‫؍‬ .001 by noninferiority). The

show abstract

Section: Transfusion Strategiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

McCullough

Vesole²,

Benjamin³

et al. 2004

Blood

365

579

View full text Add to dashboard Cite

show abstract

“…Treatment of the resultant complexes with UVA illumination leads to the formation of inter-and cross-strand links between pyrimidine bases, which prevents pathogen replication and transcription. 47 In vitro studies have shown that photochemical treatment with amotosalen and UVA does not substantially affect platelet or plasma function 40,41,48,49 and clinical trials indicated that transfusion of psoralen-treated platelets or plasma to patients does not result in adverse immunologic or hemorrhagic responses. [50][51][52][53] More than a million kits to prepare IBS platelets and plasma have been sold since the introduction of the system in Europe.…”

Section: Introductionmentioning

confidence: 99%

Photochemical Inactivation of Chikungunya Virus in Human Apheresis Platelet Components by Amotosalen and UVA Light

Tsetsarkin¹,

Sampson‐Johannes²,

Sawyer³

et al. 2013

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that recently re-emerged in Africa and rapidly spread into countries of the Indian Ocean basin and South-East Asia. The mean viremic blood donation risk for CHIKV on La Réunion reached 1.5% at the height of the 2005-2006 outbreaks, highlighting the need for development of safety measures to prevent transfusion-transmitted infections. We describe successful inactivation of CHIKV in human platelets and plasma using photochemical treatment with amotosalen and long wavelength UVA illumination. Platelet components in additive solution and plasma units were inoculated with two different strains of high titer CHIKV stock (6.0-8.0 logs/mL), and then treated with amotosalen and exposure to 1.0-3.0 J/cm 2 UVA. Based on in vitro assays of infectious virus pre-and post-treatment to identify endpoint dilutions where virus was not detectable, mean viral titers could effectively be reduced by 6.4 ± 0.6 log 10 TCID 50 /mL in platelets and 7.6 ± 1.4 logs in plasma, indicating this treatment has the capacity to prevent CHIKV transmission in human blood components collected from infected donors in or traveling from areas of CHIKV transmission.

show abstract

“…Amotosalen plus UVA treatment of platelets does not alter platelet function in in vitro tests, including: platelet count, morphology, ATP secretion, hypotonic shock response, platelet shape change, platelet aggregation, and platelet activation by p-selectin expression (13,14). The amotosalen plus UVA photoinactivation technology has received a CE mark (a symbol that shows that the goods meet the European Union's product safety standards) in Europe, and the regulatory approval process in the United States has been initiated.…”

mentioning

confidence: 99%

Trypanosoma cruziInactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV

Voorhis

Barrett²,

Eastman³

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Trypanosoma cruzi, the protozoan pathogen that causes Chagas' disease, can be found in the blood of infected individuals for their entire life span. This presents a serious challenge in safeguarding blood products. Transmission of T. cruzi from blood products is a frequent occurrence in Latin America, where Chagas' disease is endemic. This study was designed to determine whether T. cruzi could be inactivated in human platelet concentrates and plasma by a photochemical treatment process with long-wavelength UV A light (UVA, 320 to 400 nm) plus the psoralen amotosalen HCl (Cerus Corporation). Units of platelet concentrates (300 ml) and plasma (300 ml) were intentionally contaminated with approximately 10 6 T. cruzi trypomastigotes, the T. cruzi form found in the bloodstream, per ml. The viability of T. cruzi after photochemical inactivation was determined by their ability to replicate in 3T3 fibroblasts. Controls, including treatment with 150 M amotosalen or 3 J/cm 2 UVA alone, did not lead to reduction of the viability of T. cruzi in plasma or platelet concentrates. However, treatment with 150 M amotosalen plus 3 J/cm 2 UVA inactivated T. cruzi to undetectable levels in plasma and platelet concentrates. This represented a >5.4-log reduction of T. cruzi in platelet concentrates and >5.0-log reduction of T. cruzi in plasma. We conclude that the amotosalen plus UVA photochemical inactivation technology is effective in inactivating high levels of protozoan pathogens, such as T. cruzi, in platelet concentrates and plasma, as has been previously shown for numerous viruses and bacteria.

show abstract

Photochemical Treatment of Platelet Concentrates with a Novel Psoralen and UVA to Enhance the Safety of Platelet Transfusions<sub>a</sub>

Cited by 31 publications

References 28 publications

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

Photochemical Inactivation of Chikungunya Virus in Human Apheresis Platelet Components by Amotosalen and UVA Light

Trypanosoma cruziInactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV

Contact Info

Product

Resources

About